What Pergastric Treats: Main Uses and Benefits

Pergastric is commonly used to provide targeted symptomatic relief for symptoms related to physical discomfort caused by the accumulation of excess gas in the digestive tract. The active ingredient is intended for the relief of gas-related symptoms, including uncomfortable pressure, fullness, and bloating. It is generally applied across therapeutic domains where additional symptomatic support is needed to address these core manifestations.

The primary therapeutic goals include assisting with easing abdominal pressure, supporting the reduction of feelings of fullness, and helping address visible distension or bloating in conditions characterized by periods of heightened symptoms. Pergastric is considered relevant in managing episodic manifestations of gas-related discomfort, and it may be applied in specific clinical settings, such as supportive management of postoperative gas-related discomfort or as a preparatory measure for diagnostic medical imaging (like ultrasound).

“The medication may contribute to improved comfort by offering symptomatic relief that helps patients cope more steadily with symptom fluctuations, especially when symptoms interfere with routine activities.”

---

Quick Fact: Relief for Trapped Gas

Property	Description
Main Therapeutic Goal	Symptomatic relief of gas-related physical discomfort.
Key Symptom Cluster	Abdominal pressure, fullness, and distension/bloating.
Common Use Context	Episodic indigestion and post-surgical gas management.
Patient Benefit	Contributes to easing the overall symptom load during periods of heightened symptoms.

Regulatory References

1. NIH MedlinePlus overview of Simethicone

Eligibility Scope

The eligibility for Pergastric is widely established across most populations due to the active ingredient, Dimethicone (Simethicone), being not systemically absorbed.

Category	Official Regulatory Status
Contraindicated Populations	Patients with known hypersensitivity or severe allergic reaction to Dimethicone/Simethicone or any other component in the product's formulation.
Age-Related Eligibility	Approved for use in adults, children, and infants. No specific dosage adjustment is typically required for older adults (geriatric use).
Pregnancy & Lactation	Permitted for use during both pregnancy and lactation, as systemic exposure is negligible and transfer to breast milk is not anticipated.
Organ Function Status	No dose adjustment or restriction is typically cited in the regulatory labeling for patients with renal or hepatic impairment.
Conditional Restrictions	Use is restricted or inappropriate in patients with a known or suspected mechanical bowel obstruction or bowel perforation.

Connection to the overall eligibility profile: Official regulatory documents define eligibility based on the drug's inert, local action, which results in established use across all age groups and minimal functional restrictions, with the primary absolute exclusion being a documented allergy to the substance.

The official regulatory profile for Pergastric is defined by its negligible systemic exposure. As the active substance is not absorbed and is pharmacologically inert, it has no or negligible influence on the plasma concentrations of co-administered medicines. Consequently, there are no documented systemic pharmacokinetic interactions mediated by metabolic enzymes, such as Cytochrome P450 (CYP), or drug transporters. This regulatory finding confirms the absence of interaction risk for the majority of co-administered medicinal products.

However, a specific physical interaction pattern has been documented regarding Levothyroxine (a synthetic thyroid hormone). Co-administration with Pergastric may lead to impaired gastrointestinal absorption of Levothyroxine due to local physical binding within the digestive tract. To prevent this reduction in systemic exposure, a time separation between the administration of Pergastric and Levothyroxine is required. This specific interaction is noted as a relevant caution for certain populations, including infants treated for thyroid disorders. Furthermore, regulatory documentation lists no specific interactions with food, alcohol, or common herbal products.

Surface Tension Modulation and Foam Destabilization

The mechanism of action of Pergastric (Dimethicone) is non-systemic and exclusively physical, focusing on the mechanical environment of the gastrointestinal lumen rather than biological pathways. It is considered pharmacologically inert and acts as a surfactant to facilitate the physical removal of trapped gas. The primary function is to engage the physical state of gas by rapidly reducing the surface tension that stabilizes the walls of numerous small gas bubbles, thereby physically destabilizing the foam matrix within the stomach and intestines. This action involves no interaction with biological targets like receptors, enzymes, or ion channels.

Gas Coalescence and Physical Clearance

The structural collapse of the small bubbles immediately initiates coalescence, where the gas units merge into fewer, much larger bubbles. This rapid conversion promotes the physical clearance of the gas via normal physiological processes, such as belching or flatus. This mechanical outcome results in a reduction in the volume and physical stability of intraluminal gas, which was previously constrained within the small-bubble foam volume.

Official Administration Guidelines

Pergastric is an antiflatulent preparation intended exclusively for oral administration, utilizing forms such as an oral suspension, tablets, or softgels. Its usage pattern is based on the occurrence of symptoms, rather than a fixed daily schedule.

For adults and adolescents (aged 12 and over), a typical single administration ranges from 80 mg to 180 mg, depending on the specific dosage strength utilized. Standard guidelines establish a maximum limit, stipulating that the total amount of the active ingredient taken must not exceed 500 mg within a 24-hour period.

The medicine is typically taken after meals and again at bedtime to align administration with periods of potential gas formation. The medicine is designated for short-term, symptomatic use. If the underlying condition persists for longer than two weeks, the standard protocol is to discontinue use.

Specific preparation instructions apply depending on the form. Oral suspensions or drops must be shaken well prior to measurement. Chewable tablets, conversely, must be fully crushed or chewed before swallowing to ensure the proper dispersal of the antifoaming agent. Dosing is also specified for pediatric populations: infants under two years of age are directed to receive a 20 mg dose, while children two years and older are directed to receive a 40 mg dose.

Research Evidence / Overview of Studies for Pergastric

---

Evidence for Symptomatic Gas Relief in Functional Conditions

Research for Pergastric (Dimethicone) primarily involves studies exploring symptom measurement patterns in conditions characterized by fluctuating or episodic manifestations, such as functional upper gastrointestinal discomfort. To understand the medicine's role, researchers have conducted short-term Randomized Controlled Trials (RCTs) and Double-Blind Placebo-Controlled Trials. These studies monitored adults with functional dyspepsia and related functional disorders, with historical evidence evaluated in studies examining patient-reported experiences in infants with colic.

These trials were designed to collect patient-reported outcomes describing perceived discomfort. Studies explored how symptoms evolved in the observed populations, with findings describing measurement patterns observed in the studies over the defined time intervals. Specifically, outcomes related to physical discomfort, such as feelings of abdominal pressure and fullness, were measured during the short study periods. Studies contribute to the broader evidence landscape, but the research does not determine whether an individual will respond similarly, as findings describe group patterns, not personal outcomes.

Long-term effects are not fully established regarding the sustained relief or the progression of the functional disorder. The typical follow-up durations were limited, meaning the existing studies provide limited insight into whether the observed patterns continue over many months.

---

Evidence for Use in Specialized Clinical Contexts

Research for Diagnostic Procedure Preparation

Pergastric was evaluated in research exploring its use as a preparatory agent before medical procedures, such as endoscopy or rectal ultrasonography. These studies utilized Comparative Trials where the medicine was assessed against other agents or no preparation. The research examined objective outcomes, such as the visual clarity of the gastrointestinal tract during the procedure. Data show patterns related to the medicine's effect being inconsistent and potentially dependent on the patient’s existing anatomy or the procedure being performed.

Research for Flatulence and Post-Surgical Discomfort

The medicine was studied for specific conditions involving periods of heightened symptoms. For instance, researchers explored whether Pergastric was studied for flatulence in adults diagnosed with Irritable Bowel Syndrome (IBS) and for acute post-surgical gas discomfort. These studies monitored outcomes describing episodic or acute changes in symptoms like distension over short-to-medium time frames. In some cases, comparative evidence is lacking, and some trials described findings that were mixed when comparing the medicine to other agents.

---

Understanding Research Gaps and Uncertainty

Research indicates that there is limited information for long-term outcomes or the durability of effect beyond defined study intervals. Due to the generally modest sample sizes and short study durations, long-term effects are not fully established. Furthermore, the research is not designed to address any underlying functional or systemic imbalance; it primarily focuses on patient-reported outcomes related to physical discomfort.

Key Studies & References A randomized placebo-controlled trial of simethicone and cisapride for the treatment of patients with functional dyspepsia

Common questions about Pergastric (FAQ)

Q: What is Pergastric used for?

Pergastric (Omeprazole) belongs to a class of medicines called Proton Pump Inhibitors (PPIs). It works by decreasing the amount of acid your stomach makes. This medication is used to treat conditions where the stomach produces too much acid. These conditions include:

• Gastroesophageal Reflux Disease (GERD), also known as heartburn, which causes acid to back up from the stomach into the esophagus (food pipe).
• Erosive esophagitis, damage to the esophagus caused by stomach acid.
• Zollinger-Ellison Syndrome, a rare condition where the stomach makes very large amounts of acid.
• Stomach and duodenal ulcers (ulcers in the stomach and the upper part of the small intestine).
• It is also used to help heal acid damage to the stomach and esophagus and to prevent ulcers from returning.

Q: How should I take Pergastric?

Always take this medicine exactly as your doctor has told you. The dosage and how long you take it will depend on your condition. Generally, for GERD and related conditions, it is often taken once a day.

• Pergastric is usually taken 30 to 60 minutes before a meal.
• It is best to take your dose at the same time each day.
• You should swallow the capsules or tablets whole with a glass of water. Do not crush, chew, or break them. If you cannot swallow a capsule whole, talk to your doctor or pharmacist about how to properly take the medication.
• Continue taking Pergastric for the full time prescribed by your doctor, even if your symptoms improve sooner.

Q: What are the common side effects of Pergastric?

Like all medicines, Pergastric can cause side effects, although not everybody gets them. The most common side effects are usually mild and may include:

• Headache
• Abdominal pain or stomach discomfort
• Diarrhea
• Constipation
• Gas (flatulence)
• Nausea or vomiting

These common side effects often lessen as your body adjusts to the medicine. If you experience any side effects that worry you or do not go away, you should speak with your doctor or pharmacist.

Q: Can Pergastric be taken long-term?

Pergastric (Omeprazole) is often prescribed for short-term treatment, typically 4 to 8 weeks, for conditions like erosive esophagitis or ulcers. For some chronic conditions, such as Zollinger-Ellison Syndrome or to prevent recurrence of erosive esophagitis, a doctor may prescribe it for a longer duration.

• Long-term use (over a year) of PPIs like Pergastric may be associated with an increased risk of certain side effects, including bone fractures, low magnesium levels (hypomagnesemia), and Clostridium difficile-associated diarrhea.
• It is important to use the lowest effective dose for the shortest duration necessary.
• If you need to take Pergastric long-term, your doctor will periodically review your need for the medication and monitor you for any potential side effects. Do not stop taking Pergastric suddenly or change your dose without first talking to your doctor, as this may cause your symptoms to return.

Q: Does Pergastric interact with other medications?

Yes, Pergastric can interact with several other medications. It is very important to tell your doctor and pharmacist about all the prescription and non-prescription medicines, vitamins, and herbal products you are taking.

Pergastric may affect how other drugs work or be affected by them. Some key interactions include:

• Clopidogrel (a blood thinner): Taking Pergastric with this drug may reduce its effectiveness.
• Warfarin (another blood thinner): May increase the risk of bleeding.
• Methotrexate (used for cancer and autoimmune diseases): Pergastric may increase the level of methotrexate in the blood.
• Drugs that rely on stomach acid for absorption, such as certain antifungal medications (e.g., ketoconazole) and iron supplements. Pergastric may reduce their absorption.

Your doctor may adjust the doses of your other medications or monitor you closely for side effects if you are taking them with Pergastric.

The storage and disposal of Pergastric (Dimethicone) must strictly follow official regulatory guidelines to maintain its stability and ensure safety.

Storage Requirements

To preserve product quality, the medicine must be stored below 25°C (77°F) and should be protected from freezing. It is required to keep the product in its original container with the lid tightly closed to shield it from moisture and direct sunlight. For safety, the product must be secured out of the sight and reach of children.

---

Disposal Instructions

Official regulatory bodies prefer that unused or expired medicine be disposed of using a drug take-back program. If this is unavailable, the medicine must be mixed with an unappealing substance, placed in a sealed bag or container, and discarded in the household trash. The product must not be poured down the sink or flushed down the toilet.